TECOGEN INC. 8-K

What Happened
TecoGen Inc. filed an 8-K (Item 5.02) reporting that on June 26, 2026 the Compensation Committee recommended — and the Board approved — equity awards and base-salary increases for the CEO and the company's named executive officers under the 2022 Stock Incentive Plan. Grants include restricted stock for five executives and incentive stock options for the CEO and President/COO. The filing was signed July 1, 2026 by CEO Abinand Rangesh.

Key Details

• Equity grants (vest 25% per year over 4 years):
  • Abinand Rangesh, CEO: 174,081 restricted shares; 26,041 incentive stock options (exercise price $5.17).
  • Robert A. Panora, President & COO: 9,671 restricted shares; 26,041 incentive stock options (exercise price $5.17).
  • Roger Deschenes, CFO: 29,013 restricted shares.
  • Stephen Lafaille, VP Business Development: 29,013 restricted shares.
  • John K. Whiting IV, General Counsel & Secretary: 19,342 restricted shares.
• Base-salary increases: CEO Rangesh +5% to $220,500; other named executives +3% to: Panora $206,000; Deschenes $185,400; Lafaille $152,260; Whiting $185,400.
• Plan and timing: Awards granted under TecoGen’s 2022 Stock Incentive Plan and approved by the Board on June 26, 2026.

Why It Matters
These actions increase executive equity ownership and tie compensation to company performance and retention through multi-year vesting — potentially aligning management and shareholder interests. The options at $5.17 set a specific exercise price (investors can compare this to the current market price to assess potential dilution and future insider gains). Salary increases are modest cash cost increases but could raise the company’s ongoing compensation expense.